ArticleDiscover oncology2025
Investigating the interaction of ACKR1 and c-Myc in the breast carcinoma tumor microenvironment modulation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review).Oncology reports · 2026Review
- Modulation of breast cancer progression in high-altitude hypoxia by Tongqiaohuoxue Decoction via HIF-1α/VEGF signaling.Discover oncology · 2026Article
- The placental battlefield: viral strategies and immune countermeasures.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the interplay between the Atypical chemokine receptors (ACKR1)/Decoy receptor for chemokines (DARC) and key molecular markers, including CCL8, c-MYC, ALDH1, and CHEK2, in breast cancer. DARC has been implicated in various aspects of cancer progression, including tumor growth, angiogenesis, and metastasis. By analyzing the expression patterns of these markers in breast cancer tissues, we aim to understand their collective impact on tumor behaviour and identify potential therapeutic targets. Our findings reveal complex interactions between DARC and these molecular markers, suggesting their synergistic roles in promoting or repressing breast cancer progression. Understanding these relationships could lead to developing more effective and personalized therapeutic strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.